RIGL

40.4501.80%
WH

Walter H. Moos

Independent Director

Dr. Walter H. Moos, Ph.D. serves as Managing Director at Pandect Bioventures Management, LLC since October 2018. He was Chairman Emeritus of ShangPharma Innovation Inc. from December 2020 to January 2023. He serves as a Chair at Keystone Symposia On Molecular And Cellular Biology (Inc). He serves as a Director of Valitor, Inc. He served as Chief Executive Officer of ShangPharma Innovation Inc. from February 2017 to June 2020. Dr. Moos served as Vice President and Head of the bioscience division of SRI International, Inc. since March 2005. Dr. Moos served as a Consultant to Metro Vancouver Properties Corp. Dr. Moos served as Chairman and Chief Executive Officer of Migenix Corp. from January 1997 to August 2004. Dr. Moos has wealth of life sciences R&D experience, having served most recently as the President of SRI Biosciences since January 2015 until 2016 and previously in senior executive roles at MitoKor. He is also a Managing Director and co-founder of Pandect Bioventures. Dr. Moos served as the Chairman and Chief Executive Officer of MitoKor, Inc from 1997 to 2004 where he was a member of the board of directors from 2004 to 2008. From 1991 to 1997, he served as Corporate Vice President and Vice President of Research & Development in the Technologies Division of Chiron Corporation. From 1982 to 1991, Dr. Moos held several positions at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, last holding the position of Vice President of Neuroscience & Biological Chemistry. He has been Independent Director of Rigel Pharmaceuticals, Inc. since March 1997. Prior to SRI he served as Chairman and CEO of MitoKor (Migenix) and as a Vice President at Chiron (Novartis) and Warner-Lambert / Parke-Davis (Pfizer). He has served in business and scientific boards, including Amunix, Oncologic (Aduro), Onyx (Amgen), Rigel and the Biotechnology Industry Organization (BIO). He serves as an Advisor of Red Abbey Venture Partners, LLC. Dr. Moos serves as a Director of Circle Pharma, Inc., Alnis BioSciences, Inc., Anterion Therapeutics, Oncologic, Inc. and the Keystone Symposia (from 2002-2011 and again since 2014). Dr. Moos served as a Director of Migenix Inc. and Metro Vancouver Properties Corp. from August 31, 2004 to August 11, 2008. He served as Director at Amunix Pharmaceuticals, Inc. He served as a Director of Axiom Biotechnologies, the Biotechnology Industry Organization, CMPS, Mimotopes and Onyx. In addition, he has been an Adjunct Professor at the University of California, San Francisco, since 1992. Dr. Moos has been an advisor to the National Academy of Sciences and venture capital firms. He held adjunct faculty positions at the University of Michigan, Ann Arbor. Dr. Moos studied Bachelors of Arts (AB) with honors in Chemistry from Harvard University from 1972 to 1976 and a Ph.D. in Chemistry from the University of California, Berkeley from 1976 to 1982.

Positions